GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » EV-to-EBIT

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) EV-to-EBIT : -33.02 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bellevue Life Sciences Acquisition's Enterprise Value is $60.42 Mil. Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83 Mil. Therefore, Bellevue Life Sciences Acquisition's EV-to-EBIT for today is -33.02.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's EV-to-EBIT or its related term are showing as below:

BLAC' s EV-to-EBIT Range Over the Past 10 Years
Min: -2694.49   Med: 0   Max: 0
Current: -33.02

BLAC's EV-to-EBIT is ranked worse than
100% of 176 companies
in the Diversified Financial Services industry
Industry Median: 9.055 vs BLAC: -33.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bellevue Life Sciences Acquisition's Enterprise Value for the quarter that ended in Dec. 2023 was $59.03 Mil. Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83 Mil. Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.10%.


Bellevue Life Sciences Acquisition EV-to-EBIT Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition EV-to-EBIT Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -32.24

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -291.08 -156.93 -96.04 -32.24

Competitive Comparison of Bellevue Life Sciences Acquisition's EV-to-EBIT

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's EV-to-EBIT falls into.



Bellevue Life Sciences Acquisition EV-to-EBIT Calculation

Bellevue Life Sciences Acquisition's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=60.420/-1.83
=-33.02

Bellevue Life Sciences Acquisition's current Enterprise Value is $60.42 Mil.
Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-1.83/59.025975
=-3.10 %

Bellevue Life Sciences Acquisition's Enterprise Value for the quarter that ended in Dec. 2023 was $59.03 Mil.
Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004